Zhejiang Huahai Pharmaceutical Co., Ltd.

SHSE:600521 Stock Report

Market Cap: CN¥31.0b

600521 Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

Zhejiang Huahai Pharmaceutical Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zhejiang Huahai Pharmaceutical
Historical stock prices
Current Share PriceCN¥20.56
52 Week HighCN¥23.83
52 Week LowCN¥13.49
Beta0.41
1 Month Change-1.39%
3 Month Change46.02%
1 Year Change15.57%
3 Year Change-3.02%
5 Year Change-43.89%
Change since IPO775.72%

Recent News & Updates

Recent updates

Cautious Investors Not Rewarding Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Performance Completely

Feb 20
Cautious Investors Not Rewarding Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Performance Completely

Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Somewhat Strained Balance Sheet

Jan 27
Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Somewhat Strained Balance Sheet

Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Oct 22
Investors Holding Back On Zhejiang Huahai Pharmaceutical Co., Ltd. (SHSE:600521)

Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Sep 25
Here's Why Zhejiang Huahai Pharmaceutical (SHSE:600521) Has A Meaningful Debt Burden

Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Jun 20
Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Intrinsic Value Is Potentially 89% Above Its Share Price

Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

May 28
Zhejiang Huahai Pharmaceutical (SHSE:600521) Takes On Some Risk With Its Use Of Debt

There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

May 06
There May Be Some Bright Spots In Zhejiang Huahai Pharmaceutical's (SHSE:600521) Earnings

Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Mar 22
Investors Don't See Light At End Of Zhejiang Huahai Pharmaceutical Co., Ltd.'s (SHSE:600521) Tunnel

Shareholder Returns

600521CN PharmaceuticalsCN Market
7D-10.6%1.0%1.2%
1Y15.6%25.3%23.9%

Return vs Industry: 600521 underperformed the CN Pharmaceuticals industry which returned 25.3% over the past year.

Return vs Market: 600521 underperformed the CN Market which returned 23.9% over the past year.

Price Volatility

Is 600521's price volatile compared to industry and market?
600521 volatility
600521 Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement4.9%
Market Average Movement5.0%
10% most volatile stocks in CN Market8.6%
10% least volatile stocks in CN Market2.9%

Stable Share Price: 600521's share price has been volatile over the past 3 months compared to the CN market.

Volatility Over Time: 600521's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of CN stocks.

About the Company

FoundedEmployeesCEOWebsite
19899,065Bao Hua Chenwww.huahaipharm.com

Zhejiang Huahai Pharmaceutical Co., Ltd. operates as a pharmaceutical company in China and internationally. The company offers central neurological, cardiovascular, anti-viral, and other products, as well as APIs and intermediates. It also provides packaging components, such as high-density polyethylene bottles and polypropylene caps for pharmaceuticals.

Zhejiang Huahai Pharmaceutical Co., Ltd. Fundamentals Summary

How do Zhejiang Huahai Pharmaceutical's earnings and revenue compare to its market cap?
600521 fundamental statistics
Market capCN¥30.95b
Earnings (TTM)CN¥1.15b
Revenue (TTM)CN¥9.42b
26.6x
P/E Ratio
3.2x
P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
600521 income statement (TTM)
RevenueCN¥9.42b
Cost of RevenueCN¥3.57b
Gross ProfitCN¥5.85b
Other ExpensesCN¥4.71b
EarningsCN¥1.15b

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

Aug 30, 2025

Earnings per share (EPS)0.77
Gross Margin62.13%
Net Profit Margin12.16%
Debt/Equity Ratio77.7%

How did 600521 perform over the long term?

See historical performance and comparison

Dividends

1.2%
Current Dividend Yield
32%
Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/11 16:26
End of Day Share Price 2025/07/11 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zhejiang Huahai Pharmaceutical Co., Ltd. is covered by 21 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Wanhua WuChina International Capital Corporation Limited
Shanshan LiChina Merchants Securities Co. Ltd.
Ling Bo TuChina Minzu Securities